Compare Stocks: RARE, IMVT, KOD, and CGON

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$61.71 -1.3%	$70.83	$35.80 ▼ $80.97	$5.54B	0.28	987,401 shs	1.06 million shs
IMVT Immunovant	$28.41 -2.4%	$35.98	$18.74 ▼ $45.42	$6.01B	0.84	1.50 million shs	641,348 shs
KOD Kodiak Sciences	$87.63 +2.2%	$58.11	$15.83 ▼ $104.00	$5.39B	2.03	3.94 million shs	526,932 shs
RARE Ultragenyx Pharmaceutical	$15.65 -1.9%	$17.72	$12.73 ▼ $39.89	$1.57B	0.35	3.89 million shs	1.79 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	+0.48%	+1.10%	-19.55%	-9.78%	+49.22%
IMVT Immunovant	+2.54%	+5.78%	-21.96%	-26.16%	+53.97%
KOD Kodiak Sciences	-2.21%	-2.66%	+153.79%	+107.15%	+375.24%
RARE Ultragenyx Pharmaceutical	+0.19%	+5.14%	+2.18%	-40.71%	-51.87%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$61.71 -1.3%	$70.83	$35.80 ▼ $80.97	$5.54B	0.28	987,401 shs	1.06 million shs
IMVT Immunovant	$28.41 -2.4%	$35.98	$18.74 ▼ $45.42	$6.01B	0.84	1.50 million shs	641,348 shs
KOD Kodiak Sciences	$87.63 +2.2%	$58.11	$15.83 ▼ $104.00	$5.39B	2.03	3.94 million shs	526,932 shs
RARE Ultragenyx Pharmaceutical	$15.65 -1.9%	$17.72	$12.73 ▼ $39.89	$1.57B	0.35	3.89 million shs	1.79 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	+0.48%	+1.10%	-19.55%	-9.78%	+49.22%
IMVT Immunovant	+2.54%	+5.78%	-21.96%	-26.16%	+53.97%
KOD Kodiak Sciences	-2.21%	-2.66%	+153.79%	+107.15%	+375.24%
RARE Ultragenyx Pharmaceutical	+0.19%	+5.14%	+2.18%	-40.71%	-51.87%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	2.70	Moderate Buy	$87.50	41.79% Upside
IMVT Immunovant	2.58	Moderate Buy	$44.00	54.88% Upside
KOD Kodiak Sciences	2.63	Moderate Buy	$104.71	19.50% Upside
RARE Ultragenyx Pharmaceutical	2.45	Hold	$33.65	115.02% Upside

Current Analyst Ratings Breakdown

Latest RARE, IMVT, KOD, and CGON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	CGON CG Oncology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	RARE Ultragenyx Pharmaceutical	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Neutral	$16.00
10/14/2026	RARE Ultragenyx Pharmaceutical	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
10/12/2026	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$96.00 ➝ $126.00
10/6/2026	KOD Kodiak Sciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/6/2026	RARE Ultragenyx Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/2/2026	IMVT Immunovant	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/30/2026	KOD Kodiak Sciences	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral	$103.00
9/28/2026	KOD Kodiak Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$112.00
9/28/2026	KOD Kodiak Sciences	Lifesci Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$85.00 ➝ $145.00
9/28/2026	KOD Kodiak Sciences	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$80.00 ➝ $120.00

(Data available from 10/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$4.04M	1,353.95	N/A	N/A	$9.33 per share	6.61
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.19 per share	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.97 per share	N/A
RARE Ultragenyx Pharmaceutical	$717M	2.15	N/A	N/A	($0.83) per share	-18.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	11/13/2026 (Estimated)
IMVT Immunovant	-$505.61M	-$2.82	N/A	N/A	N/A	N/A	-69.59%	-62.49%	11/9/2026 (Estimated)
KOD Kodiak Sciences	-$229.97M	-$4.19	N/A	N/A	N/A	N/A	-273.23%	-85.48%	11/12/2026 (Estimated)
RARE Ultragenyx Pharmaceutical	-$575M	-$5.84	N/A	N/A	N/A	-81.79%	N/A	-44.40%	11/3/2026 (Estimated)

Latest RARE, IMVT, KOD, and CGON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/13/2026	Q3 2026	CGON CG Oncology	-$0.8341	N/A	N/A	N/A	$0.55 million	N/A
11/12/2026	Q3 2026	KOD Kodiak Sciences	-$1.06	N/A	N/A	N/A	N/A	N/A
11/9/2026	Q2 2027	IMVT Immunovant	-$0.7370	N/A	N/A	N/A	$7.10 million	N/A
11/3/2026	Q3 2026	RARE Ultragenyx Pharmaceutical	-$1.11	N/A	N/A	N/A	$182.03 million	N/A
8/13/2026	Q2 2026	KOD Kodiak Sciences	-$0.9565	-$1.05	-$0.0935	-$1.05	N/A	N/A
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/6/2026	Q1 2027	IMVT Immunovant	-$0.6289	-$0.75	-$0.1211	-$0.75	$7.10 million	$7.10 million
8/4/2026	Q2 2026	RARE Ultragenyx Pharmaceutical	-$1.22	-$0.90	+$0.32	-$0.90	$183.08 million	$214.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	22.22	22.20
IMVT Immunovant	N/A	7.27	7.27
KOD Kodiak Sciences	N/A	2.49	2.49
RARE Ultragenyx Pharmaceutical	N/A	1.73	1.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
IMVT Immunovant	47.08%
KOD Kodiak Sciences	89.06%
RARE Ultragenyx Pharmaceutical	97.67%

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	4.80%
IMVT Immunovant	1.90%
KOD Kodiak Sciences	44.40%
RARE Ultragenyx Pharmaceutical	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	142	88.64 million	84.39 million	Optionable
IMVT Immunovant	315	206.55 million	202.63 million	Optionable
KOD Kodiak Sciences	124	62.85 million	34.94 million	Optionable
RARE Ultragenyx Pharmaceutical	1,371	98.59 million	93.46 million	Optionable

RARE, IMVT, KOD, and CGON Headlines

Recent News About These Companies

Ultragenyx Pharmaceutical (RARE) Receives a Buy from Piper Sandler

October 23 at 12:50 PM | theglobeandmail.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $33.65 According to Brokerages

October 21 at 4:28 AM | marketbeat.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock: Insider Howard Horn Sells 7,066 Shares

October 21 at 4:23 AM | americanbankingnews.com

Ultragenyx Pharmaceutical Inc. $RARE Stock Acquired by Assenagon Asset Management S.A.

October 21 at 3:04 AM | marketbeat.com

Insider Selling: Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells 7,066 Shares of Stock

October 20 at 4:22 AM | insidertrades.com

Ultragenyx Pharmaceutical Enters Settlement With Navinta Over Dojolvi

October 19, 2026 | finance.yahoo.com

Insider Selling: Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells $107,897.82 in Stock

October 19, 2026 | marketbeat.com

Ultragenyx, Baylor Reach Settlement on DOJOLVI Patents

October 19, 2026 | tipranks.com

UBS sets USD 16.00 target for Ultragenyx Pharmaceutical stock

October 18, 2026 | ad-hoc-news.deA

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Moved Up to "Hold" by UBS Group

October 17, 2026 | marketbeat.com

Ultragenyx Pharmaceutical (RARE) Receives a New Rating from a Top Analyst

October 16, 2026 | theglobeandmail.com

RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week

October 15, 2026 | zacks.com

UBS Group Begins Coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE)

October 15, 2026 | marketbeat.com

Ultragenyx makes swift $413M return on FDA review vouchers after summer of gene therapy nods

October 15, 2026 | fiercepharma.comF

Ultragenyx Pharmaceutical to Sell Priority Review Voucher for $203M

October 14, 2026 | marketwatch.com

Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher for $203 Million

October 14, 2026 | finance.yahoo.com

Ultragenyx To Sell Rare Pediatric Disease Priority Review Voucher For $203 Mln

October 14, 2026 | rttnews.com

Ultragenyx to sell Fayuvi FDA priority review voucher for $203M

October 14, 2026 | seekingalpha.com

Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?

October 14, 2026 | zacks.com

Ultragenyx Sells FDA Priority Review Voucher for Cash

October 14, 2026 | tipranks.com

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million

October 14, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RARE, IMVT, KOD, and CGON Company Descriptions

CG Oncology NASDAQ:CGON

$61.71 -0.83 (-1.33%)

Closing price 04:00 PM Eastern

Extended Trading

$61.74 +0.03 (+0.05%)

As of 07:30 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Immunovant NASDAQ:IMVT

$28.41 -0.69 (-2.37%)

Closing price 04:00 PM Eastern

Extended Trading

$28.43 +0.02 (+0.07%)

As of 07:30 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Kodiak Sciences NASDAQ:KOD

$87.63 +1.85 (+2.16%)

Closing price 04:00 PM Eastern

Extended Trading

$87.05 -0.58 (-0.66%)

As of 07:55 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Ultragenyx Pharmaceutical NASDAQ:RARE

$15.65 -0.30 (-1.88%)

Closing price 04:00 PM Eastern

Extended Trading

$15.68 +0.03 (+0.16%)

As of 07:42 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RARE, IMVT, KOD, and CGON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RARE, IMVT, KOD, and CGON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RARE, IMVT, KOD, and CGON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RARE, IMVT, KOD, and CGON Company Descriptions

CG Oncology NASDAQ:CGON

Immunovant NASDAQ:IMVT

Kodiak Sciences NASDAQ:KOD

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RARE, IMVT, KOD, and CGON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RARE, IMVT, KOD, and CGON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RARE, IMVT, KOD, and CGON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RARE, IMVT, KOD, and CGON Company Descriptions

CG Oncology NASDAQ:CGON

Immunovant NASDAQ:IMVT

Kodiak Sciences NASDAQ:KOD

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools